TNFSF10 and neoplasm: Our in vivo results (Figures 6 and 7) are consistent with previous reports, which showed that TRAIL treatment on its own failed to reduce tumor size in mice with preclinical xenografts.[62, 63] All treatment intervals, except for the 1 h timepoint, between the TRAIL injection and FUS exposure for the multi‐dose in vivo studies in Figures 6 and 7 showed smaller tumor volume compared to the PBS, FUS, and TRAIL conditions.